Drugs / Iobenguane I-123 Injection
Iobenguane I-123 Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02656329 | Dec 2015 → May 2018 | heart failure | GE Healthcare | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iobenguane I-123 Injection | “Iobenguane I-123 Injection, AdreView.” NCT02656329 ↗ |
| Modality | Diagnostic / imaging agent | “AdreView™ imaging” NCT02656329 ↗ |
| Route | Intravenous | “1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection).” NCT02656329 ↗ |